LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study-Reference-Cited by-同舟云学术

LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study

Published:2020-09 Issue: Volume:31 Page:S1191
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Moehler M.,Shitara K.,Garrido M.,Salman P.,Shen L.,Wyrwicz L.,Yamaguchi K.,Skoczylas T.,Campos Bragagnoli A.,Liu T.,Schenker M.,Yanez P.,Tehfe M.,Poulart V.,Cullen D.,Lei M.,Kondo K.,Li M.,Ajani J.A.,Janjigian Y.Y.

Funder

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

Oncology,Hematology

Cited by 192 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Significance of dysregulated M2 macrophage and ESR2 in the ovarian metastasis of gastric cancer;Translational Cancer Research;2024-06

2. Safety and clinical efficacy of immune checkpoint inhibitors in advanced gastric cancer in the real world;Journal of Cancer Research and Clinical Oncology;2024-04-08

3. Deciphering drug resistance in gastric cancer: Potential mechanisms and future perspectives;Biomedicine & Pharmacotherapy;2024-04

4. Comparative efficacy of PD-1 blockade in patients with dMMR/MSI-H metastatic colorectal or gastric cancer: a global retrospective study;ESMO Gastrointestinal Oncology;2024-03

5. PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study;Investigational New Drugs;2024-02-12